ProShares UltraShort Nasdaq Biotechnology (NASDAQ:BIS) Short Interest Update

ProShares UltraShort Nasdaq Biotechnology (NASDAQ:BIS) saw a significant growth in short interest in the month of December. As of December 15th, there was short interest totalling 10,300 shares, a growth of 22.6% from the November 30th total of 8,400 shares. Based on an average trading volume of 12,700 shares, the short-interest ratio is presently 0.8 days.

ProShares UltraShort Nasdaq Biotechnology Price Performance

NASDAQ:BIS traded up $0.36 during mid-day trading on Friday, hitting $17.85. 5,573 shares of the company’s stock traded hands, compared to its average volume of 14,111. The firm has a 50 day moving average of $16.32 and a two-hundred day moving average of $15.73. ProShares UltraShort Nasdaq Biotechnology has a 12 month low of $14.05 and a 12 month high of $21.10.

ProShares UltraShort Nasdaq Biotechnology Increases Dividend

The firm also recently declared a dividend, which will be paid on Tuesday, December 31st. Stockholders of record on Monday, December 23rd will be issued a dividend of $0.2064 per share. The ex-dividend date of this dividend is Monday, December 23rd. This is a positive change from ProShares UltraShort Nasdaq Biotechnology’s previous dividend of $0.15.

Institutional Investors Weigh In On ProShares UltraShort Nasdaq Biotechnology

A hedge fund recently bought a new stake in ProShares UltraShort Nasdaq Biotechnology stock. Jane Street Group LLC purchased a new stake in shares of ProShares UltraShort Nasdaq Biotechnology (NASDAQ:BIS) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 10,520 shares of the company’s stock, valued at approximately $158,000. Jane Street Group LLC owned 4.78% of ProShares UltraShort Nasdaq Biotechnology as of its most recent SEC filing.

About ProShares UltraShort Nasdaq Biotechnology

ProShares Ultra Nasdaq Biotechnology (the Fund) seeks investment results for a single day only, not for longer periods. The Fund seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day’s returns compounded over the period, which will very likely differ from twice (200%) the return of the Nasdaq Biotechnology Index (the Index) for that period.